Clinicopathological characteristics and prognosis of synchronous brain metastases from non-small cell lung cancer compared with metachronous brain metastases
Frontiers in Oncology · 22.05.2024 · 14
DOI: 10.3389/fonc.2024.1400792 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 22.05.2024. Verfasst von Jing Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Graduate, Dalian Medical University, Dalian, Liaoning, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Brain metastasis (BM) from non-small cell lung cancer (NSCLC) is a serious complication severely affecting patients’ prognoses. We aimed to compare the clinicopathological features and prognosis of synchronous and metachronous BM from NSCLC.
Methods
Clinical data of 461 patients with brain metastases from NSCLC who visited the Cancer Hospital of China Medical University from 2005 to 2017 were retrospectively collected. We analyzed the pathophysiological characteristics of synchronous and metachronous BM from NSCLC and survival rates of the patients. Propensity score matching analysis was used to reduce bias between groups. In addition, we used the Kaplan-Meier method for survival analysis, log-rank test to compare survival rates, and Cox proportional hazards regression model for multivariate prognosis analysis.
Results
Among 461 patients with BM, the number of people who met the inclusion criteria was 400 cases, and after 1:2 propensity score matching,130 had synchronous BM and 260 had metachronous BM. The survival time was longer for metachronous BM in driver mutation-negative patients with squamous cell carcinoma than synchronous BM. Conversely, metachronous and synchronous BM with gene mutations and adenocarcinoma showed no differences in survival time. Multivariate analysis showed that metachronous BM was an independent prognostic factor for overall survival. Furthermore, the pathological type squamous cell carcinoma and Karnofsky Performance Status score <80 were independent risk factors affecting overall survival.
Conclusion
BM status is an independent factor influencing patient outcome. Moreover, synchronous and metachronous BM from NSCLC differ in gene mutation profile, pathological type, and disease progression and hence require different treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Graduate, Dalian Medical University, Dalian, Liaoning, China.
- Department of Radiotherapy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
- School of Graduate, China Medical University, Shengyang, Liaoning, China.
- Department of Breast Surgery, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
- Department of Radiotherapy, Cancer Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Radiotherapy, Cancer Hospital of Dalian University of Technology, Shenyang, Liaoning, China.
Zitieren
APA
Li, J., Zhang, X., Wang, Y., Jin, Y., Song, Y., & Wang, T. (2024). Clinicopathological characteristics and prognosis of synchronous brain metastases from non-small cell lung cancer compared with metachronous brain metastases. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1400792
Vancouver
Li J, Zhang X, Wang Y, Jin Y, Song Y, Wang T. Clinicopathological characteristics and prognosis of synchronous brain metastases from non-small cell lung cancer compared with metachronous brain metastases. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1400792
BibTeX
@article{Li2024,
author = {Li, Jing and Zhang, Xiaofang and Wang, Ye and Jin, Yi and Song, Yingqiu and Wang, Tianlu},
title = {Clinicopathological characteristics and prognosis of synchronous brain metastases from non-small cell lung cancer compared with metachronous brain metastases},
journal = {Frontiers in Oncology},
year = {2024},
volume = {14},
doi = {10.3389/fonc.2024.1400792}
}
EUVIMED